MedTrace Logo

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

NCT01069328 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2013-11-13

No results posted yet for this study

Summary

To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.

Conditions

Interventions

DRUG

Nexavar (Sorafenib, BAY43-9006)

Sorafenib 200 mg orally BID interrupted dosing

DRUG

Nexavar (Sorafenib, BAY43-9006)

Sorafenib 400 mg orally BID interrupted dosing

DRUG

Bevacizumab

Bevacizumab 2.5 mg/kg intravenously

DRUG

Bevacizumab

Bevacizumab 5 mg/kg intravenously

DRUG

Bevacizumab

Bevacizumab 7.5 mg/kg intravenously

DRUG

Bevacizumab

Bevacizumab 10 mg/kg intravenously

DRUG

Paclitaxel

Paclitaxel 200 mg/m² intravenously

DRUG

Carboplatin

Carboplatin AUC 6 intravenously

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2011-09-30
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01069328 on ClinicalTrials.gov